Dougherty Wealth Advisers’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Dougherty Wealth Advisers’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-20	Closed	-$1.52K	–	130
2023 Q1	$1.52K	Buy	+20	New	+$1.66K	﹤0.01%	125

Other funds holding XBI

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return

APF

Alaska Permanent Fund Juneau, Alaska $1.51B AUM 22.23% 1-Year Est. Return

Dougherty Wealth Advisers's XBI Position: Q2 2023 in Review

Dougherty Wealth Advisers sold out of State Street SPDR S&P Biotech ETF (XBI) in Q2 2023, closing a stake of 20 shares — an estimated $1.52K sold.

Dougherty Wealth Advisers first reported a position in XBI in Q1 2023 and held it in 1 quarter. The position peaked at $1.52K in Q1 2023. 712 funds tracked by Wall St. Rank hold XBI as of Q2 2023.

Dougherty Wealth Advisers reported no remaining State Street SPDR S&P Biotech ETF position as of Q2 2023 after selling out during the quarter.
Dougherty Wealth Advisers sold 20 State Street SPDR S&P Biotech ETF shares in Q2 2023, an estimated $1.52K.
Dougherty Wealth Advisers first reported a position in State Street SPDR S&P Biotech ETF in Q1 2023 and held it in 1 quarter.
Dougherty Wealth Advisers's State Street SPDR S&P Biotech ETF position peaked at $1.52K in Q1 2023.
712 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2023.

Based on Dougherty Wealth Advisers's 13F filing for Q2 2023, filed 3 Aug 2023.